Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775

What is it about?

What is already known on this topic Lenvatinib plus pembrolizumab is approved in multiple countries and recommended in treatment guidelines for patients with advanced endometrial cancer that progressed following prior systemic therapy. The current analysis addresses whether lenvatinib plus pembrolizumab provides long-term (5 years) clinically meaningful and durable benefits in participants with previously treated, advanced endometrial cancer. What this study adds Five-year follow-up results from Study 309/KEYNOTE-775 demonstrate continued durable benefit with lenvatinib plus pembrolizumab versus chemotherapy in patients with previously treated, advanced endometrial cancer. The safety profile of lenvatinib plus pembrolizumab was manageable, with no new safety signals identified.

Featured Image

Photo by Europeana on Unsplash

Photo by Europeana on Unsplash

Why is it important?

These findings lend further support for the use of lenvatinib plus pembrolizumab as a standard of care therapy in patients with previously treated, advanced endometrial cancer.